Searchable abstracts of presentations at key conferences in endocrinology

ea0016p134 | Clinical cases | ECE2008

Optimization of chronic disease patient management: a pilot project on Sandostatin® LAR® treatment via homecare service

Roemmler J , Schopohl J , Seibling S , Petersenn S , Rinke A , Gress T M

In chronic diseases patient (pat) often need continuous med treatment. In acromegaly and neuroendocrine tumors (GEP-NET), long term monthly injections of somatostatin analogues as Sandostatin® LAR® (SA®) are the treatment of choice. Problems regarding pat management and drug application might arise in not-specialized centers such as general practicioners (GP). To optimize pat’ management and compliance a homecare project* wa...

ea0026p198 | Pituitary | ECE2011

Effects on metabolic parameters after 12-month treatment with a new once-a-week sustained release recombinant growth hormone (LB03002) in adult patients with GH deficiency (GHD)

Roemmler J , Gockel A , Otto B , Bidlingmaier M , Schopohl J

Introduction: GH substitution in GH deficiency (GHD) must be subcutaneously administered daily. Recently, a new sustained release formulation of GH (LB03002) has been developed which has to be injected only once per week. As a sub-study to the double-blind, randomized, placebo-controlled, multicenter, phase-III-study we performed this prospective study to evaluate influences of the new GH formulation on metabolic parameters and the hormones leptin and ghrelin in adult patients...

ea0011p634 | Neuroendocrinology and behaviour | ECE2006

Glucose-suppressed GH levels compared with IGF-I levels in patients with acromegaly

Steffin B , Gutt B , Roemmler J , Bidlingmaier M , Schopohl J

Nadir growth hormone (GH) levels after oral glucose tolerance test (OGTT) as well as random insulin-like growth-factor I (IGF-I) levels, given as multiples of the upper limit of normal [xULN], were used to evaluate biochemical activitiy of acromegalic patients. The development of new, more sensitive GH assays makes it necessary to reevaluate the cut off values of the GH nadir after OGTT.In a cross sectional study, we evaluated nadir GH concentrations dur...

ea0029oc10.2 | Pituitary Clinical 2 | ICEECE2012

Food intake regulating hormones in adult craniopharyngioma patients

Roemmler J. , Geigenberger V. , Otto B. , Bidlingmaier M. , Dimopoulou C. , Stalla G. , Schopohl J.

Introduction: Patients with craniopharyngeoma often have disturbances of the hypothalamic–pituitary axis and serious comorbidities as obesity. We hypothesized, that the pattern of hormones regulating the nutritional status is worsened in adult patients with craniopharyngioma (CP) compared to adult patients with non-functioning pituitary adenoma (NFPA).Methods: We included 33 patients with CP (m=16, f=17, median age: 48 years (26–7...

ea0029p97 | Adrenal cortex | ICEECE2012

Diagnosis of Cushing’s syndrome by automatic face classification using frontal and side-view photographs

Kosilek R. , Schopohl J. , Grunke M. , Dimopoulou C. , Stalla G. , Reincke M. , Gunther M. , Wurtz R. , Schneider H.

Background: Cushing’s syndrome is a disease that presents with clear symptoms and causes considerable harm to the body if left untreated, yet often remains undiagnosed for prolonged periods of time. Face-classification software might recognize typical changes of the face and thus aid in diagnosing the disease early as we have previously shown in the classification of acromegaly.Methods: Using a regular compact digital camera, we took frontal and sid...

ea0029p1405 | Pituitary Clinical | ICEECE2012

Long-term use of pasireotide in Cushing’s disease: 24-month safety results from a randomized phase III study

Bertherat J , Ludlam W , Pivonello R , Maldonado M , Trovato A , Hughes G , Gu F , Schopohl J , Salgado L

Introduction: Rapid and sustained decreases in UFC and significant improvements in signs and symptoms were seen in a large, randomized, 12-month phase III study of pasireotide in Cushing’s disease. The safety profile of pasireotide was found to be similar to that of other somatostatin analogues, with the exception of hyperglycemia-related AEs (reported in 72.8% of patients). This abstract reports safety data from a 12-month extension to this phase III trial.<p class="...

ea0029p1410 | Pituitary Clinical | ICEECE2012

Long-term pasireotide use leads to improvements in the biochemical parameters of Cushing’s disease: 24-month results from a randomized phase III study

Schopohl J , Bertherat J , Ludlam W , Maldonado M , Trovato A , Hughes G , Gu F , Salgado L , Pivonello R

Introduction: The large, randomized, phase III study of pasireotide in Cushing’s disease found that pasireotide treatment resulted in rapid and sustained decreases in UFC levels and in significant improvements in signs and symptoms over 12 months of treatment. A 12-month extension of this trial has recently completed, and the results are reported here.Methods: Patients with persistent/recurrent or de novo (if not surgical candidates) Cushing&...

ea0026p248 | Pituitary | ECE2011

Detection of acromegaly by automatic face classification software

Schneider H J , Kosilek R , Gunther M , Rommler J , Stalla G K , Sievers C , Reincke M , Schopohl J , Wurtz R

Acromegaly is accompanied by increased morbidity and mortality. The delay between onset of first symptoms and diagnosis of the disease is 6 to 10 years. Acromegaly causes typical changes of the face. We hypothesized that face classification software might help distinguishing between subjects with and without acromegaly on regular photographs and, thus, might help improving early recognition of acromegaly.Methods: We took frontal and side photographs of t...

ea0029p1406 | Pituitary Clinical | ICEECE2012

Pasireotide treatment is associated with improvements in hypertension: 12-month results from a large phase III study in Cushing’s disease

Pivonello R , Petersenn S , Newell-Price J , Gu F , Maldonado M , Trovato A , Hughes G , Salgado L , Lacroix A , Schopohl J , Biller B

Introduction: Patients with Cushing’s disease (CD) have an increased risk of hypertension (HTN). phase III data have shown that pasireotide leads to rapid reductions in UFC levels and significant improvements in CD symptoms. We now present further analyses of these data, evaluating the effects of pasireotide on HTN in patients with CD.Methods: Patients with persistent/recurrent or de novo (if not surgical candidates) CD and UFC≥1.5 time...

ea0011oc20 | Clinical endocrinology | ECE2006

A European prospective real-life observational study of Quality of Life in patients with acromegaly

Webb SM , Colao A , Caron P , Carvalheiro M , Ertürk E , Pokrajac-Simeunovic A , Schopohl J , Tsagarakis S , Pearson IV , Badia X , Caglio S , Vincenzi B

The primary aim of this study, the largest European, single evaluation, observational trial to date, was to evaluate the impact of acromegaly on health-related quality of life (HRQoL) in patients with biochemically documented active disease, receiving Sandostatin® LAR® at a dose prescribed by their physician for at least 3 months. Secondary objectives were to investigate the relationships between HRQoL and subpopulations based on exploratory var...